48 results about "Tumor-Derived" patented technology

The disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer (SCLC) having a high tumor mutational burden (TMB) status comprising administering to the subject a monotherapy comprising an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody. The present disclosure also provides a method for identifying a subject suitable for treatment with an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.

A rapid, ultrasensitive and inexpensive nanoplasmon-enhanced scattering (nPES) assay that directly quantifies tumor-derived EVs from as little as 1 μL of plasma is described herein. This assay uses binding of gold nanospheres and nanorods with EV- and tumor-derived EV-specificities to produce a local plasmon effect that enhances tumor-derived EV detection sensitivity and specificity. This nPES approach is also a non-invasive method for assessing pancreatic cancer stage and treatment response that can be easily refined for clinical use, and is readily adapted for diagnosis and monitoring of other conditions with disease-specific EV proteins.

The application discloses a separation-free plasma tumor-derived extracellular vesicle detection method, relates to the technical field of biology, and comprises CD63, HER2, GPC1 or / and EpCAM; probe sequences are shown in SEQ ID NO.1-SEQ ID NO.4; the probe is applied to the extracellular vesicle detection reagent in the separation-free plasma, single EVs imaging analysis, detection of the image of a single EV after direct dilution of plasma, dynamic immune detection, and statistics of the number of specifically combined EVs. The application applies the separation-free extracellular vesicle detection probe to the immune detection reagent, avoids the separation process of plasma EVs, does not need to use fluorescence detection, can characterize the single EVs binding kinetics, and can detect 1 target EVs in 350 background particles.

The application discloses application of tumor-derived acellular extracellular matrix in preparation of a drug for promoting angiogenesis and tissue regeneration. The application proposes a strategy for regulating tissue regeneration based on a tumor-derived acellular extracellular matrix microenvironment, combines the high similarity between a tumor microenvironment and a regeneration microenvironment such as angiogenesis, and constructs a novel angiogenesis-promoting biomaterial, so that high-efficiency regeneration is realized in various tissue defects. In addition, the characteristics of rapid proliferation of tumor tissues break through the production capacity bottleneck of a raw material source of a traditional acellular extracellular matrix, and provide sustainable biological raw materials for large-scale production. The application successfully solves the problem that a specific tissue-derived acellular extracellular matrix is difficult to regenerate in a complex damage microenvironment.

The present invention relates to the field of pharmacogenomics and in particular to detecting the presence or absence of methylated ANKRD13B and / or FOXF2 DNA derived from a tumor in blood or blood-derived samples or in other body fluids that contain DNA released from a tumor. This detection is useful for a minimally invasive diagnosis of cancers and the invention provides methods and oligonucleotides suitable for this purpose.

Disclosed herein are DNA amplification methods for quantifying DNA fragments of a target DNA in a sample by size. This can be used, for example, to detect tumor-derived viral DNA in blood sample and distinguish it from larger viral DNA from non-tumor sources. In particular, disclosed herein are methods of detecting, monitoring or treating a human papilloma virus (HPV)-associated malignancy in a subject that involves detecting a presence or absence of at least one circulating tumor-derived HPV DNA in a sample from the subject. Kits for accomplishing the same are also provided.

The invention provides a preparation method of SPF (specific pathogen free) pigskin extracellular matrix (ECM) hydrogel. The preparation method comprises the following steps: S1, collecting SPF pigskin and pretreating; s2, the pretreated SPF pigskin is subjected to degreasing treatment; s3, sterilizing and disinfecting the freeze-dried powder, and then carrying out enzymolysis; s4, adjusting the pH and osmotic pressure of supernate after enzymolysis to obtain a hydrogel product. The source of the hydrogel product does not contain non-biological source materials at all, establishment of a three-dimensional cell culture environment and growth of cultured cells, especially organoids are facilitated, and meanwhile the problems of tumor sources, batch differences, high cost, potential safety hazards and the like of existing hydrogel products such as Matrigel and the like are solved. Experimental results show that the pigskin ECM hydrogel with different concentrations and from different ages can support the growth of intestinal organs, and the number of the organs cultured by the SPF pigskin ECM hydrogel with the concentration of 3 mg / mL is even more than that of Matrigel.

The application relates to the technical field of nanomaterials, in particular to an EpCAM aptamer modified nanomaterial and a preparation method and application thereof, wherein the nanomaterial takes carboxylated mesoporous silica nanoparticles as a carrier, and an EpCAM specific DNA aptamer is covalently coupled to the surface of the nanomaterial; the sequence of the EpCAM specific DNA aptamer is shown as SEQ ID No. 1. The nanomaterial can specifically capture tumor-derived exosomes (EVs) in blood, and can realize sensitive detection of EVs in the 7-day (early stage) and 21-day (late stage) stages of an HT29 colon cancer model and the 7-day stage of an A549 / H460 lung cancer model, thereby providing a minimally invasive liquid biopsy new tool for early diagnosis of colon cancer and lung cancer, and solving the inherent limitation problems of sensitivity and specificity of existing diagnosis means in cancer detection.

Disclosed herein are compositions of antigen-presenting tumor cells (APTCs) and tumor-derived antigen-presenting vesicles (Tumor-APVs) derived from APTCs and methods of their use.

The present disclosure relates to attenuated yet immunogenically potentiated tumor-derived extracellular vesicle compositions and uses thereof. The present disclosure was completed by confirming that the extracellular vesicles secreted by tumor cells are attenuated yet immunogenically potentiated through a process of treating tumor cells with verteporfin, and the extracellular vesicles of the present disclosure can be used as a vaccine composition, etc.

This invention belongs to the field of biomedical technology and provides the application of exosome-derived TRIM59 inhibitors in regulating macrophage M2 polarization and combating oral squamous cell carcinoma. The TRIM59 inhibitor uses exosomes derived from oral squamous cell carcinoma tissue as carriers, with the surface modified with the M2 macrophage-targeting molecule M2pep, internally loaded with TRIM59 inhibitors and KRT6B inhibitors, and loaded with STING pathway agonists. This invention relies on the microenvironment targeting and membrane surface targeting modification of tumor-derived exosomes to precisely deliver TRIM59 inhibitors and KRT6B inhibitors to M2 macrophages and tumor cells. By silencing TRIM59, the resistance of M2 macrophages to the STING pathway is relieved, forming a temporal synergistic effect of first unlocking and then activating with the STING agonist, driving macrophages to M1 polarization.

The invention belongs to the technical field of biological detection, and particularly relates to a synchronous detection sensor for two membrane proteins of tumor-derived small extracellular vesicles based on CRISPR / Cas9. Comprising the following steps: (1) aptamers AptEGFR and AptPD-L1, which are targeted to EGFR (epidermal growth factor receptor) and PD-L1; the magnetic nano particles are modified with an aptamer AptEpCAM (Aptamer EpCAM); (2) a compound of sgRNA1, sgRNA2 and Cas9 protein, wherein the sgRNA1 and the sgRNA2 can be hybridized with nucleic acid sequences at the tail parts of the aptamers AptEGFR and AptPD-L1; the long-stem hairpin probe W1 and the long-stem hairpin probe W2 can be respectively identified by the sgRNA1 and the sgRNA2 and can be cut by the Cas9 protein to release ssDNA Act1 and Act2; (3) hairpin probes H1, H2, H3 and H4; cHA1 is formed by the Act1, the hairpin probe H1 and the hairpin probe H2, and CHA2 is formed by the Act2, the hairpin probe H3 and the hairpin probe H4. The sensor provided by the invention has potential clinical application value in lung cancer screening and auxiliary diagnosis.

Various embodiments of the present invention provide compositions of tumor-infiltrating lymphocytes (TILs) enriched with tumor-reactive cells. The embodiments also provide methods for producing tumor-reactive TILs enriched with tumor-reactive cells, and the use of the provided enriched tumor-reactive TILs for treating cancer in humans or other subjects. According to the embodiments, a tumor-reactive T cell enriched pharmaceutical T lymphocyte infiltration (TIL) composition comprises an oligoclonal population of tumor-infiltrating T cells, including tumor-derived CD4+ and CD8+ T cells, with up to 40 clones constituting 40% of the TCR frequency in the population. Embodiments of the present invention are particularly useful for treating tumors that are resistant or refractory to conventional chemotherapy, or that have become resistant or refractory.

The invention discloses an anti-osteosarcoma combined pharmaceutical composition and application thereof. The combined pharmaceutical composition comprises a TNF alpha inhibitor and a chemotherapeutic drug. According to the invention, the TNF alpha inhibitor and the traditional chemotherapeutic drug are combined for use for the first time to resist osteosarcoma, so that the purposes of synergistic tumor inhibition, toxicity reduction and sensitization are achieved. By intervening a neglected chemotherapy side reaction pathway of tumor-liver axis, tumor-derived extracellular vesicles are blocked to induce Kupffer cells to release TNF alpha, liver lipid droplet deposition is reduced, and expression (including Cyp1a2, Cyp2b10, Cyp3a11 and the like) of CYP metabolic enzymes is recovered, so that the metabolic capability of the liver to chemotherapy drugs is improved, and toxic and side effects are reduced. From the perspective of chemotherapy tolerance and toxic and side effect control, cardiotoxicity and myelosuppression are remarkably reduced, the overall tolerance to a chemotherapy regimen is improved, and a safer and more efficient strategy is provided.

The invention belongs to the technical field of medicines, and particularly relates to a construction method of a peripheral blood circulating tumor DNA and RNA co-construction library and a kit for detecting tumor mutation. The invention provides a peripheral blood circulating tumor DNA and RNA co-construction library and a construction method thereof. By adopting the ctDNA and ctRNA co-established library, more tumor-derived mutations can be detected, mutation types missed by the ctDNA library are found, and mutation characteristic identification of tumor cells of tumor patients is realized more accurately and sensitively.

The present invention discloses a non-invasive early screening method and system for cancer based on the length distribution characteristics of cfDNA fragments. This method uses a relatively low-depth whole-genome sequencing method to statistically analyze the differences in the fragment length distribution characteristics of tumor-derived cfDNA and healthy individual-derived cfDNA, establish an early screening model for cancer, and achieve non-invasive early screening for cancer. The scheme of the present invention focuses on the characteristic of blood cfDNA fragment size to distinguish ctDNA from non-tumor-derived cfDNA. It does not rely on the mutation detection of oncogenes or tumor suppressor genes, and eliminates the interference caused by clonal hematopoietic mutations. Secondly, the data of the embodiments of the present invention show that the size characteristics of blood cfDNA fragments can be used to distinguish between healthy people and early-stage tumor patients. Finally, due to the use of low-depth whole-genome sequencing technology, the detection costs involved in the scheme of the present invention are greatly reduced, which is conducive to future applications in the field of early screening of malignant tumors.

To provide methods for classifying genetic mutations detected in cell-free nucleic acids as tumor or non-tumor origin.SOLUTION: Methods for differentiating tumor and non-tumor origin nucleic acid variants in cell-free nucleic acid (cfNA) samples include generating a tumor variant dataset comprising a population of reference tumor-related genetic variants. The tumor variant dataset comprises frequency of observance data among reference samples that comprises reference bodily fluid (e.g., plasma) samples and reference non-bodily fluid (e.g., non-plasma) samples for tumor-related genetic variants in the population of reference tumor-related genetic variants. The methods further include determining ratios of the frequency of observance data between the reference samples for tumor-related genetic variants in the population of reference tumor-related genetic variants to produce a relative prevalence dataset.SELECTED DRAWING: Figure 2

The invention discloses a pharmaceutical composition containing a tumor-derived acellular extracellular matrix and an application of the pharmaceutical composition. The invention provides a strategy for regulating and controlling tissue regeneration based on a tumor-derived acellular extracellular matrix microenvironment, a novel angiogenesis promoting biological material is constructed by combining the high similarity of a tumor microenvironment and a regeneration microenvironment such as angiogenesis, and high-efficiency regeneration is realized in various tissue defects. In addition, due to the characteristic of rapid proliferation of the tumor tissue, the productivity bottleneck of a traditional acellular extracellular matrix raw material source is broken through, and sustainable biological raw materials are provided for large-scale production. The method successfully solves the problem that a specific tissue-derived acellular extracellular matrix is difficult to regenerate in a complex damaged microenvironment.

The invention relates to a lung nodule benign and malignant diagnosis method based on a proximity linking technology. The method comprises the following steps: 1) extracting and purifying exosome; s1) preparing plasma; s2) preparing an aqueous two-phase system; s3) collecting the exosome; and 2) detecting a protein signal. The method for diagnosing benign and malignant pulmonary nodules based on the proximity link technology is integrally based on a peripheral blood exosome extraction and purification technology, tumor-derived proteins are concentrated and enriched, then protein signals are subjected to exponential amplification by utilizing a trace hydroxylated lysine protein detection technology, and the detection result is obtained. Therefore, the detection sensitivity and accuracy are improved.

This present disclosure relates to systems and methods for detecting HLA alterations (e.g., HLA loss of heterozygosity or HLA copy number alterations) in a sample from a subject. The disclosed methods may comprise, for example, receiving sequence read data derived from a tumor sample and a normal sample from the subject; receiving a subject-specific reference sequence for an HLA region of the subject's genome; determining, based on the sequence read data and the subject-specific reference sequence, a number of unique tumor-derived sequence reads and unique normal-derived sequence reads for each of a first allele and a second allele of an HLA gene; and detecting an HLA alteration for the HLA gene based on a tumor allelic ratio and a normal allelic ratio that are determined based on the number of unique tumor-derived sequence reads and unique normal-derived sequence reads for the first allele and second alleles of the HLA gene.

The invention relates to a gene expression based biomarker that is predictive of patient clinical need for treatment that includes a PD-1 antagonist, wherein the gene expression based biomarker comprises five or more genes selected from the genes listed in Table 1 or Table 2 disclosed herein. More specifically, a negative level of a gene expression based biomarker wherein the biomarker comprises five or more genes selected from the genes listed in Table 1 or a positive level of a gene expression based biomarker wherein the biomarker comprises 5 or more genes selected from the genes listed in Table 2 is associated with favorable prognosis in a patient with cancer. Also provided are methods of treating a cancer patient with a PD-1 antagonist that were identified as positive for a gene expression based biomarker of the invention. The disclosure also provides methods and kits for testing tumor samples for the biomarkers.

The invention relates to a tumor-derived IgG (immunoglobulin G) antibody coupled human recombinant ferritin loaded CpG nano tumor vaccine. The nano tumor vaccine comprises a human recombinant ferritin core-shell structure, a tumor-derived IgG antibody is coupled to the surface of the human recombinant ferritin core-shell structure, and CpG is carried on the core of the human recombinant ferritin core-shell structure. The invention also relates to application of the nano tumor vaccine in treatment of melanoma.

Neuroendocrine tumors (NETs) are a class of highly heterogeneous tumors derived from neuroendocrine cells. Synaptic vesicle 2 (SV2) protein is a novel marker of NETs, and there are three subtypes of SV2A, SV2B and SV2C, wherein the structure of SV2C is more stable than the other two, and the largest cavity ring L4 thereof is the most important binding area with toxins. The present application obtains a nanobody of the extracellular soluble part L4 of SV2 by screening through phage display technology, and the nanobody labeled with a fluorescein, a small molecule of a chemical toxin or a nuclide is used to prepare a probe molecule, and the result can be specifically combined with neuroendocrine tumor cells. The present application provides a nanobody of the extracellular soluble part L4 of SV2, and the nanobody can be applied in the preparation of diagnostic and therapeutic preparations for neuroendocrine tumors.

Provided herein are methods for differentiating from each other, at least in part, using a computer, a tumor-derived nucleic acid variation and a non-tumor (e.g., a potential-undetermined clonal hematopoietic (CHIP))-derived nucleic acid variation in a test sample obtained from a test subject, and a method for differentiating, from each other, a tumor-derived nucleic acid variation and a non-tumor (e.g., a potential-undetermined clonal hematopoietic (CHIP))-derived nucleic acid variation in a test sample obtained from the test subject. Other aspects relate to methods of treating a disease in a subject. Yet other aspects include related systems and computer readable media for differentiating tumor-derived and non-tumor-derived nucleic acid variations from each other.

Methods and kits for isolating tumour-derived exosomes by immunocapture with an anti CA-IX antibody, quantifying tumour-related nucleic acid sequences from the isolated exosomes and determining in vitro the presence of a tumour in a subject are provided.

This application relates to a method and apparatus for deep methylation sequencing assisted by a machine learning classifier of methylation patterns, which allows for sequencing at dilutions down to 10-10. ‑4 This application describes a methylation sequencing method that can detect the presence and / or abundance of low-frequency ctDNA in a sample, potentially offering advantages in cancer screening and treatment efficacy evaluation.

The application belongs to the technical field of biological detection, and particularly relates to a homogeneous fluorescence instant tumor liquid biopsy strategy based on DNA functionalized nanospheres. 2+ Multifunctional integrated nanospheres. Based on the functional integration of the nanospheres, one-step detection of circulating tumor cells (CTCs) or tumor-derived exosomes (TDEs) is realized, and in combination with a test strip and a smartphone red, green and blue (RGB) analysis technology, a variety of analysis modes including fluorescence detection and smartphone-RGB are provided, a rapid and sensitive tumor liquid biopsy instant detection method is constructed, convenient analysis of "drop and see" is realized, and the rapid and convenient detection demand of tumor liquid biopsy is met, and an effective means is provided for early disease screening.

Provided herein are methods for enriching tumor derived EVs or brain-derived EVs from a biological sample, e.g. a biofluid, using a lectin or glycan-binding fragment thereof and an isolation component (e.g., a solid media). The present disclosure also provides compositions and kits for isolating brain-derived EVs or tumor derived EVs, and compositions comprising an isolated population of brain-derived EVs or tumor derived EVs.

The application discloses tumor-derived exosomes, complement C3 as a marker for kidney cancer metastasis and application thereof, and belongs to the tumor immunity field.The first aspect of the application relates to a kidney cancer metastasis detection kit, comprising: a reagent for detecting complement protein C3, and application of the reagent in preparation of a product for detecting kidney cancer metastasis.The second aspect of the application relates to application of a reagent for inhibiting complement protein C3 in preparation of a medicine for treating kidney cancer.The application provides a new thought for diagnosis and treatment of kidney cancer metastasis, and provides a new research direction for development of a kidney cancer related kit and medicine.

A disease classification method includes determining, using a predictive model, whether cell-free nucleic acid samples are tumor-derived or non-tumor derived based on at least one of the cell-free nucleic acid score or a tumor fraction regression (TFR) score satisfying a respective threshold. The TFR score is determined based on a quantification of an observed tumor-associated aberrant methylation of each of a plurality of cell-free nucleic acid samples using a TFR model. The TFR score includes a fraction of molecules of the plurality of cell-free nucleic acid samples that indicate a tumor. The cell-free nucleic acid score is indicative of the presence of a tumor, and is based on at least one of epigenetic factors or genomic alterations of the cell-free nucleic acid samples.